Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Bitcoin Depot (BTM) Q4 2025 Earnings Transcript

View original at finance.yahoo.com
Bitcoin Depot (BTM) Q4 2025 Earnings Transcript Image source: The Motley Fool. DATE Monday, Mar. 16, 2026 at 10 a.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin Depot Inc. is best positioned to navigate evolving regulatory environment as largest operator in North America with one of the most robust compliance programs

    60% confidence
  • 2026 is likely to be a challenging year for core BTM business with revenue expected to decline between 30% to 40% year over year

    60% confidence
  • Number of kiosks will likely stay flat or down slightly depending on how relocations are handled for states that pass particularly negative bills

    60% confidence
  • Users who have completed at least one transaction between 2016 and 12/31/2025 have transacted a total of $5,311 on average, up 5% from previous year

    60% confidence
  • Can accelerate Cut growth substantially by investing more into marketing and engineering teams

    60% confidence
  • Currently do not anticipate further expansion of profit share program moving forward

    60% confidence
  • 2025 was a strong year for Bitcoin Depot Inc. with growth across the majority of key operating and financial metrics and meaningful progress executing on long-term strategy

    60% confidence
  • Cut and ReadyBox represent important steps in evolution from single-product operator into broader fintech platform

    60% confidence
  • Do not expect Cut and ReadyBox to have material impact on overall revenue in current year

    60% confidence
  • Cut revenue will definitely be below $5 million for 2026

    60% confidence
  • Have not seen changes internationally like what is happening in U.S., still actively working on two more countries to launch in late Q1 or early Q2

    60% confidence
  • 2027 should be much less regulatory activity, though could be some revisions to existing state bills

    60% confidence
  • Regulatory measures ultimately raise industry standards and reinforce advantages of scale, compliance infrastructure, and regulatory engagement

    60% confidence
  • Do not know exactly what regulatory changes will happen in 2026, states will pass additional measures limiting economics but uncertain how many states or what bills will pass

    60% confidence
  • Q4 results declined year over year primarily driven by recently enacted state regulations that introduced transaction size caps and enhancements to compliance standards

    60% confidence
  • By end of 2026, will have seen 80% to 90% of states decide where their stance is on regulation, at least initially

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Bitcoin Depot (BTM) Q4 2025 Earnings Transcript — Source | Via News | ViaNews EU